DURHAM, NC, and LIEGE, BELGIUM - May 31, 2010, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, today announced that its Annual General Shareholders' Meeting (AGM) held on 28 May, 2010, approved the appointment of Ms. Hilde Windels, Mr. Edward L. Erickson, and Mr. Mark Myslinski to the Board of Directors, as well as all other agenda items of the AGM. The appointment of the new directors is effective immediately for a period until the 2013 AGM.
Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "I am delighted that our shareholders have appointed these directors who bring a wealth of relevant experience, and vision to OncoMethylome. Our management and board look forward to working together and benefit from their strong record of achievements in finance, life sciences and the commercial lab service industry that will prove extremely valuable to OncoMethylome's further growth."
Ms. Hilde Windels (1965), a Belgian national, is currently CFO of two biotechnology companies, Pronota NV and SEPS Pharma NV. For nearly 10 years she was CFO of Devgen NV, a publicly listed Belgian biotech company, where she led the company's IPO on Euronext Brussels, managed investor relations, and also acted as Head of the pharma business unit during 2008. Prior to working in the biotech sector, she was employed for over 10 years at ING Bank. Mrs. Windels will also serve on OncoMethylome's Audit Committee. Ms. Windels holds a Master's degree in applied economics from Leuven University.
Mr. Edward L. Erickson (1946), an American national, has served as President, CEO, and Director of over a dozen life sciences companies. During his tenure at these firms he played a central role in numerous financial and business transactions, overseeing product development programs and launches, and shaping strategies for growth. Over the last 20 years, Mr. Erickson was president and CEO of three formerly NASDAQ-listed biotech companies (Immunicon Corporation, DepoTech Corporation, and Cholestech Corporation). He is currently the interim CEO of BioNanomatrix Inc., board member of Metabolon Inc., Molecular Biometrics Inc., and Zetek LLC. Mr. Erickson holds an MBA from Harvard University.
Mr. Mark Myslinski (1955), an American national, is President and CEO of RedPath Integrated Pathology Inc., a US-based CLIA diagnostics laboratory that will be acquired by the French company ExonHit Therapeutics. Mr. Myslinski will be the CEO of Redpath and the president of the global diagnostics business unit of ExonHit. Additionally, he serves on the Management Committee of ExonHit. Mr. Myslinski has over 30 years of experience in the healthcare industry, with a focus on diagnostics, and has held management positions at Johnson & Johnson, Baxter, American Hospital Supply Corporation and various venture-backed start-ups. Mr. Myslinski holds an MBA from Ohio University.
Dr. Robert Timmins (age 77) and Mr. Gerard Vaillant (age 69) have retired from the Board effective May 28, 2010. "We are grateful to Dr. Timmins for his leadership, diligence, and hard work, provided to the company over the last seven as Chairman of the Board. We also thank Mr. Vaillant for his contribution to the Board over the last year", added Dr. Jan Groen.
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to help the physician accurately detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience Division, Roche, Merck KGaA and Qiagen
|
